LLY

997.38

+1.26%↑

JNJ

242.29

+0.47%↑

ABBV

230.3

+0.46%↑

NVS

161.45

+0.82%↑

AZN

196.17

+2.64%↑

LLY

997.38

+1.26%↑

JNJ

242.29

+0.47%↑

ABBV

230.3

+0.46%↑

NVS

161.45

+0.82%↑

AZN

196.17

+2.64%↑

LLY

997.38

+1.26%↑

JNJ

242.29

+0.47%↑

ABBV

230.3

+0.46%↑

NVS

161.45

+0.82%↑

AZN

196.17

+2.64%↑

LLY

997.38

+1.26%↑

JNJ

242.29

+0.47%↑

ABBV

230.3

+0.46%↑

NVS

161.45

+0.82%↑

AZN

196.17

+2.64%↑

LLY

997.38

+1.26%↑

JNJ

242.29

+0.47%↑

ABBV

230.3

+0.46%↑

NVS

161.45

+0.82%↑

AZN

196.17

+2.64%↑

Home・Akciju saraksts・AnaptysBio Inc

AnaptysBio Inc

Atvērts

SektorsVeselības aprūpe

60.5 6.81

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

55.61

Max

60.81

Galvenie mērījumi
By Trading Economics
Ienākumi	54M 15M
Pārdošana	54M 76M
Peļņas marža	19.802
Darbinieki	136
EBITDA	57M 38M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+47.21% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 1. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	528M 1.5B
Iepriekšējā atvēršanas cena	53.69
Iepriekšējā slēgšanas cena	60.5

Ziņu noskaņojums

By Acuity

44%

56%

133 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

19.25 / 21.135 Atbalsts un pretestība

AnaptysBio Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 9. marts 18:13 UTC

Iegādes, apvienošanās, pārņemšana

Shell to Sell Jiffy Lube to Monomoy in $1.3 Billion Deal -- Update

2026. g. 9. marts 17:20 UTC

Galvenie ziņu notikumi

U.S. Ag Industry Calls for Government Intervention on Fertilizer Prices

2026. g. 9. marts 17:15 UTC

Iegādes, apvienošanās, pārņemšana

Shell to Sell Jiffy Lube and Premium Velocity to Monomoy for $1.3 Billion

2026. g. 10. marts 00:00 UTC

Galvenie ziņu notikumi

Why Iranian Regime Change Would Transform Global Energy Markets -- WSJ

2026. g. 9. marts 23:52 UTC

Tirgus saruna

Gold Steady; May Be Supported by Dollar's Weakness -- Market Talk

2026. g. 9. marts 23:50 UTC

Tirgus saruna

Nikkei May Rise as Fears About Higher Energy Prices Ease -- Market Talk

2026. g. 9. marts 23:50 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 9. marts 23:46 UTC

Tirgus saruna

Galvenie ziņu notikumi

Correction to Crude Prices Market Talk on March 9

2026. g. 9. marts 23:42 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Fall Amid Developments That Could Help Supply -- Market Talk

2026. g. 9. marts 23:08 UTC

Galvenie ziņu notikumi

Front-Month WTI Futures Drop 7.9% to $87.29/bbl, ICE Data Show

2026. g. 9. marts 23:07 UTC

Galvenie ziņu notikumi

Front-Month WTI Futures Fall After Trump Says Iran War Will Be Over 'Very Soon'

2026. g. 9. marts 21:29 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue Now Fully Owns Peru's Canariaco Copper Project

2026. g. 9. marts 21:28 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue Completes Acquisition of Remaining Alta Copper Shares

2026. g. 9. marts 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. marts 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. marts 20:47 UTC

Galvenie ziņu notikumi

The 24 Hours When Oil Markets Went Wild -- WSJ

2026. g. 9. marts 20:33 UTC

Galvenie ziņu notikumi

Stock Market Today: Oil Slips, Stocks Bounce on Trump War-Progress Comments Headline -- WSJ

2026. g. 9. marts 20:14 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Moves Lower As Trump Says War Could End Soon -- Market Talk

2026. g. 9. marts 19:33 UTC

Galvenie ziņu notikumi

High Oil Prices Could Crimp Convenience Store Margins -- Barrons.com

2026. g. 9. marts 19:17 UTC

Tirgus saruna

Galvenie ziņu notikumi

Prospect of Added Supply From Oil Reserves Ease Inflation Fears -- Market Talk

2026. g. 9. marts 19:14 UTC

Tirgus saruna

Oil Settles Off Highs As G7 Discusses Tapping Reserves -- Market Talk

2026. g. 9. marts 19:00 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Lower -- Market Talk

2026. g. 9. marts 18:23 UTC

Tirgus saruna

Galvenie ziņu notikumi

BofA Drops Canada Rate-Cut Call on Higher Oil Prices -- Market Talk

2026. g. 9. marts 17:58 UTC

Iegādes, apvienošanās, pārņemšana

Shell to Sell Jiffy Lube to Monomoy in $1.3B Deal -- Update

2026. g. 9. marts 17:57 UTC

Iegādes, apvienošanās, pārņemšana

Activist Investors Target Food Companies as Growth Slows. Lamb Weston Is the Latest. -- Barrons.com

2026. g. 9. marts 17:41 UTC

Galvenie ziņu notikumi

U.S. and Western Allies Turn to Reserves to Counteract Gulf Oil Crisis -- WSJ

2026. g. 9. marts 17:41 UTC

Tirgus saruna

Galvenie ziņu notikumi

Reports of Saudi Production Shut-Ins Keep Bid in Crude -- Market Talk

2026. g. 9. marts 17:08 UTC

Tirgus saruna

Canada Rate Outlook Shifts From Long Pause to Late 2026 Hike -- Market Talk

2026. g. 9. marts 17:04 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 9. marts 17:04 UTC

Tirgus saruna

Galvenie ziņu notikumi

Treasury Yields, Dollar Off Highs as G7 Tackles Oil Shock -- Market Talk

Salīdzinājums

Cenas izmaiņa

AnaptysBio Inc Prognoze

Cenas mērķis

By TipRanks

47.21% augšup

Prognoze 12 mēnešiem

Vidējais 81.57 USD 47.21%

Augstākais 140 USD

Zemākais 50 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

9 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 9 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

19.25 / 21.135Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

133 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.